29
Views
4
CrossRef citations to date
0
Altmetric
Review

Positive modulators of the AMPA receptor

, &
Pages 1539-1548 | Published online: 25 Feb 2005
 

Abstract

Alterations in the excitatory neurotransmission by AMPA-type (α-methyl3-hydroxy-5-methyl-4-isoxazol-4-ylpropionic acid) glutamate receptors may be involved in the aetiology of neurological diseases such as Alzheimer’s disease and schizophrenia. The potentiation of AMPA-receptor mediated synaptic transmission by allosteric positive modulators of this receptor (Ampakines™) may have beneficial behavioural effects in these diseases. The development of compounds acting as Ampakines has led to CX516 (Ampalex™, Cortex Pharmaceuticals), which has reached the early stage of clinical trials for schizophrenia. The number of structural classes of compounds reported in the patent literature as positive modulators of the AMPA receptor is expanding from the earlier benzoyl piperidine (aniracetam) and thiazide (cyclothiazide, diazoxide) chemical series. This review covers the patent literature from the last five years (January 1995 to June 2000) in which there are claims for positive modulators of the AMPA receptor.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.